EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors

Michal Pochopien, Anna Tytuła, Mondher Toumi, Aletta Falk, Nicoletta Martone, Zalmai Hakimi, Daniel Eriksson iD

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02841-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2024. Verfasst von Michal Pochopien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Assignity, Kraków, Poland. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi, Stockholm, Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Recombinant factor IX (rFIX) and recombinant FIX Fc fusion protein (rFIXFc) are standard half-life and extended half-life FIX replacement therapies, respectively, and represent established treatment options indicated for adults and children with haemophilia B. These FIX replacement therapies can be administered as prophylaxis (to prevent bleeding) or 'on-demand' (to stop bleeding). This analysis aimed to estimate the cost-effectiveness of once-weekly prophylaxis with rFIXFc versus on-demand treatment with rFIX in patients with haemophilia B without inhibitors in the Italian healthcare setting. METHODS: A Markov model was developed to assess a hypothetical cohort of adolescent or adult male patients (≥ 12 years) with haemophilia B (FIX level of ≤ 2 IU/dL) without inhibitors. Model inputs were derived from the pivotal phase 3 clinical studies for rFIXFc and rFIX, published literature and assumptions when published data were unavailable. The model employed a lifelong time horizon with 6-monthly transitions between health states, and it estimated total costs, total quality-adjusted life years (QALYs), number of bleeds, number of surgeries and incremental cost-effectiveness ratio. RESULTS: rFIXFc prophylaxis was associated with lower total costs per patient (€5,308,625 versus €6,564,510) and greater total QALYs per patient (15.936 versus 11.943) compared with rFIX on-demand; rFIXFc prophylaxis was therefore the dominant treatment strategy. The model also demonstrated that rFIXFc prophylaxis was associated with fewer incremental bleeds (- 682.29) and surgeries (- 0.39) compared with rFIX on-demand. CONCLUSIONS: rFIXFc prophylaxis provides improved health outcomes and lower costs, and represents a cost-effective treatment option compared with rFIX on-demand for adolescent and adult male patients with haemophilia B. This comparative assessment of cost-effectiveness should help to inform both clinicians and healthcare policy makers when making treatment decisions for patients with haemophilia B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXHemophilia BImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdolescentAdultChildHumansMaleMiddle AgedYoung AdultCost-Benefit AnalysisHemorrhageItalyMarkov ChainsQuality-Adjusted Life YearsRecombinant Proteins

Stichwörter der Autor:innen

Cost-effectiveness analysisFactor IXHaemophilia BHaemorrhagePrimary preventionQuality-adjusted life yearsRecombinant fusion proteins

Substanzen

Factor IXfactor IX Fc fusion proteinImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsRecombinant Proteins

Autor:innen und Institutionen

  • Assignity, Kraków, Poland.
  • Health Economics and Outcomes Research Department, Putnam PHMR, Kraków, Poland.
  • Department of Public Health, Aix-Marseille University, Marseille, France.
  • Sobi, Stockholm, Sweden.
  • Sobi, Milan, Italy.
  • Sobi, Stockholm, Sweden. Daniel.Eriksson@sobi.com.

ORCID-Profile: Daniel Eriksson

Förderung

  • Sobi, Stockholm, Sweden

Zitieren

APA

Pochopien, M., Tytuła, A., Toumi, M., Falk, A., Martone, N., Hakimi, Z., & Eriksson, D. (2024). Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in Therapy. https://doi.org/10.1007/s12325-024-02841-w

Vancouver

Pochopien M, Tytuła A, Toumi M, Falk A, Martone N, Hakimi Z, et al. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors. Advances in Therapy. 2024. doi:10.1007/s12325-024-02841-w

BibTeX
@article{Pochopien2024,
  author = {Pochopien, Michal and Tytuła, Anna and Toumi, Mondher and Falk, Aletta and Martone, Nicoletta and Hakimi, Zalmai and Eriksson, Daniel},
  title = {Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02841-w}
}
Kostenlos starten →